B. Riley Securities Maintains Buy on Journey Medical, Raises Price Target to $12
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst Kalpit Patel maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to $12.
B. Riley Securities analyst Kalpit Patel maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to $12.